Advertisement

International Journal of Hematology

, Volume 110, Issue 1, pp 50–58 | Cite as

Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells

  • Ko K. MaungEmail author
  • Mitchell E. Horwitz
Progress in Hematology Recent progress in allogeneic stem cell transplantation using alternative stem cell sources

Abstract

In patients with hematologic malignancies, the outcome of umbilical cord blood transplantation has improved and is now comparable to that of matched unrelated donor transplantation. However, the limitation of using umbilical cord blood has been a delay in both hematopoietic and immunologic recovery. Strategies have been proposed to overcome these limitations. One strategy involves ex vivo expansion of the umbilical cord blood unit prior to transplantation. A second strategy involves exposure of the umbilical cord blood graft to compounds aimed at improving homing and engraftment following transplantation. Many of these strategies are now being tested in late phase multi-center clinical trials. If proven cost effective and efficacious, they may alter the landscape of donor options for allogeneic stem cell transplantation.

Keywords

Umbilical cord blood Expansion Manipulation Stem cell transplantation Hematopoietic recovery Hematopoietic progenitor cell 

Notes

Compliance with ethical standards

Conflict of interest

Ko Maung does not report any conflict of interest. He is supported by NIH T32HL007057 grant. Mitchell Horwitz has received research support from, and has served as a consultant for Gamida Cell Ltd.

References

  1. 1.
    Peffault de Latour R, Brunstein CG, Porcher R, Chevallier P, Robin M, Warlick E, et al. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. Biol Blood Marrow Transplant. 2013;19(9):1355–60.CrossRefGoogle Scholar
  2. 2.
    Smith AR, Baker KS, Defor TE, Verneris MR, Wagner JE, Macmillan ML. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol Blood Marrow Transplant. 2009;15(9):1086–93.CrossRefGoogle Scholar
  3. 3.
    Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. Blood. 2003;101(12):5061–7.CrossRefGoogle Scholar
  4. 4.
    Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013;121(5):752–8.CrossRefGoogle Scholar
  5. 5.
    Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343–7.CrossRefGoogle Scholar
  6. 6.
    Milner LA, Kopan R, Martin DI, Bernstein ID. A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors. Blood. 1994;83(8):2057–62.Google Scholar
  7. 7.
    Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein ID. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood. 2005;106(8):2693–9.CrossRefGoogle Scholar
  8. 8.
    Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232–6.CrossRefGoogle Scholar
  9. 9.
    Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood. 2010;115(4):757–65.CrossRefGoogle Scholar
  10. 10.
    Moretta A, Andriolo G, Lisini D, Martinetti M, Pasi A, Rebulla P, et al. In vitro evaluation of graft-versus-graft alloreactivity as a tool to identify the predominant cord blood unit before double cord blood transplantation. Biol Blood Marrow Transplant. 2012;18(7):1108–18.CrossRefGoogle Scholar
  11. 11.
    Delaney C, Milano F, Shelly H, Nicoud I, Bernstein ID. Infusion of non-hla matched, off-the-shelf ex vivo expanded cord blood progenitor cells in patients undergoing myeloablative cord blood transplantation is safe and decreases the time to neutrophil recovery. Biol Blood Marrow Transplant. 2012;18(2):S203.CrossRefGoogle Scholar
  12. 12.
    Milano F, Cox E, Heimfeld S, Bernstein I, Applebaum F, Delaney C. Non-HLA matched, ex-vivo expanded cord blood product significantly improves kinetics of hematopoietic recovery and results in excellent survival in patients undergoing cord blood transplantation. In: EHA congress; 15 June 2018. 2018.Google Scholar
  13. 13.
    Peled T, Landau E, Mandel J, Glukhman E, Goudsmid NR, Nagler A, et al. Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol. 2004;32(6):547–55.CrossRefGoogle Scholar
  14. 14.
    Peled T, Mandel J, Goudsmid RN, Landor C, Hasson N, Harati D, et al. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy. 2004;6(4):344–55.CrossRefGoogle Scholar
  15. 15.
    de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008.Google Scholar
  16. 16.
    Stiff PJ, Montesinos P, Peled T, Landau E, Goudsmid NR, Mandel J, Hasson N, Olesinski E, Glukhman E, Snyder DA, Cohen EG, Kidron OS, Bracha D, Harati D, Ben-Abu K, Freind E, Freedman LS, Cohen YC, Olmer L, Barishev R, Rocha V, Gluckman E, Horowitz MM, Eapen M, Nagler A, Sanz G. Cohort-controlled comparison of umbilical cord blood transplantation using carlecortemcel-L, a single progenitor-enriched cord blood, to double cord blood unit transplantation. Biol Blood Marrow Transplant. 2018;24(7):1463–70.CrossRefGoogle Scholar
  17. 17.
    Peled T, Shoham H, Aschengrau D, Yackoubov D, Frei G, Rosenheimer GN, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol. 2012;40(4):342–355 e1.CrossRefGoogle Scholar
  18. 18.
    Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. 2014;124(7):3121–8.CrossRefGoogle Scholar
  19. 19.
    Horwitz ME, Wease S, Blackwell B, Valcarcel D, Frassoni F, Boelens JJ, Nierkens S, Jagasia M, Wagner JE, Kuball J, Koh LP, Majhail NS, Stiff PJ, Hanna R, Hwang WYK, Kurtzberg J, Cilloni D, Freedman LS, Montesinos P, Sanz G. Nicotinamide-expanded single UCB transplantation. J Clin Oncol 2019 (in press).Google Scholar
  20. 20.
    Briddell RA, Hartley CA, Smith KA, McNiece IK. Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood. 1993;82(6):1720–3.Google Scholar
  21. 21.
    McNiece I, Harrington J, Turney J, Kellner J, Shpall EJ. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy. 2004;6(4):311–7.CrossRefGoogle Scholar
  22. 22.
    Horwitz ME, Frassoni F. Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation. Cytotherapy. 2015;17(6):730–8.CrossRefGoogle Scholar
  23. 23.
    Horwitz ME. Ex vivo expansion or manipulation of stem cells to improve outcome of umbilical cord blood transplantation. Curr Hematol Malig Rep. 2016;11(1):12–8.CrossRefGoogle Scholar
  24. 24.
    de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012;367(24):2305–15.CrossRefGoogle Scholar
  25. 25.
    Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345–8.CrossRefGoogle Scholar
  26. 26.
    Wagner JE, Brunstein CG, Boitano AE, DeFor TE, McKenna D, Sumstad D, Blazar BR, Tolar J, Le C, Jones J, Cooke MP, Bleul CC. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2016;18(1):144–55.CrossRefGoogle Scholar
  27. 27.
    Wagner JE, Brunstein CG, Defor TE, Boitano AE, McKenna DH, Sumstad D, Sanna B, Bleul CC, Cooke M. Single cord blood units (CBU) expanded with an aryl hydrocarbon receptor (AHR) antagonist, demonstrate uniform engraftment and rapid hematopoietic recovery. In: BMT tandem meetings; Salt Lake City. 2018.Google Scholar
  28. 28.
    Fares I, Chagraoui J, Gareau Y, Gingras S, Ruel R, Mayotte N, Csaszar E, Knapp DJ, Miller P, Ngom M, Imren S, Roy DC, Watts KL, Kiem HP, Herrington R, Iscove NN, Humphries RK, Eaves CJ, Cohen S, Marinier A, Zandstra PW, Sauvageau G. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science. 2014;345(6203):1509–12.CrossRefGoogle Scholar
  29. 29.
    Fares I, Chagraoui J, Lehnertz B, MacRae T, Mayotte N, Tomellini E, Aubert L, Roux PP, Sauvageau G. EPCR expression marks UM171-expanded CD34+ cord blood stem cells. Blood. 2017;129(25):3344–51.Google Scholar
  30. 30.
    North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447(7147):1007–11.CrossRefGoogle Scholar
  31. 31.
    Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013;122(17):3074–81.CrossRefGoogle Scholar
  32. 32.
    Ratajczak J, Reca R, Kucia M, Majka M, Allendorf DJ, Baran JT, et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood. 2004;103(6):2071–8.CrossRefGoogle Scholar
  33. 33.
    Reca R, Mastellos D, Majka M, Marquez L, Ratajczak J, Franchini S, et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood. 2003;101(10):3784–93.CrossRefGoogle Scholar
  34. 34.
    Brunstein CG, McKenna DH, DeFor TE, Sumstad D, Paul P, Weisdorf DJ, et al. Complement fragment 3a priming of umbilical cord blood progenitors: safety profile. Biol Blood Marrow Transplant. 2013;19(10):1474–9.CrossRefGoogle Scholar
  35. 35.
    Hidalgo A, Weiss LA, Frenette PS. Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally. J Clin Invest. 2002;110(4):559–69.CrossRefGoogle Scholar
  36. 36.
    Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, et al. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy. 2014;16(1):84–9.CrossRefGoogle Scholar
  37. 37.
    Xia L, McDaniel JM, Yago T, Doeden A, McEver RP. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood. 2004;104(10):3091–6.CrossRefGoogle Scholar
  38. 38.
    Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Javni JA, Shpall EJ, Zweidler-Mckay PA. Non-fucosylated CB CD34+ cells represent a good target for enforced fucosylation to improve engraftment following cord blood transplantation. Cytotherapy. 2017;19(2):285–92.CrossRefGoogle Scholar
  39. 39.
    Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015;125(19):2885–92.CrossRefGoogle Scholar
  40. 40.
    Anand S, Thomas S, Hyslop T, Adcock J, Corbet K, Gasparetto C, Lopez R, Long GD, Morris AK, Rizzieri DA, Sullivan KM, Sung KD, Sarantopoulos S, Chao NJ, Horwitz ME. Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization. Biol Blood Marrow Transplant. 2017;23:1151–7.CrossRefGoogle Scholar
  41. 41.
    de Koning C, Horwitz ME, Sanz G, Jagasia M, Wagner JE, Stiff PJ, Hanna R, Cilloni D, Boelens JJ, Nierkens S. Rapid and robust CD4+ and CD8+ T-, NK-, B-cell, dendritic cell, and monocyte reconstitution after nicotinamide-expanded cord blood transplantation. In: Transplantation & cellular therapy of ASBMT and CIBMTR; 20–24 February 2019; Houston. 2019.Google Scholar
  42. 42.
    Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol. 2012;40(6):445–56.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Hematology and Medical Oncology FellowDuke University School of MedicineDurhamUSA
  2. 2.Adult Blood and Marrow Transplant ProgramDuke University School of MedicineDurhamUSA

Personalised recommendations